Fermentation
HMO Series
Recombinant Yeast Fermentation | ≥98% Target Purity
3rd-Gen Precision Yeast Synthesis
Yeast-Based HMO Production
Legacy HMO production relies on engineered E. coli expression systems, which carry inherent endotoxin (LPS) risk. Our precision yeast platform uses a food-grade yeast chassis to support HMO production with a lower endotoxin-management burden, which can be important for infant nutrition and closely reviewed formulations.
Lower endotoxin-management burden
Yeast cells do not introduce the same lipopolysaccharide profile associated with gram-negative bacterial hosts, helping simplify downstream control strategies.
Yeast-host production chain
Built on a food-grade yeast chassis rather than an E. coli route, which supports a cleaner technical narrative for some applications.
99.9% Purity | pH 6.7 | Moisture < 0.2%
Standardized physical properties across all HMO variants. Verified by independent ISO 17025 accredited laboratories.
Download Our Independent GRAS Conclusion Report
Morika Bio | Human Milk Oligosaccharides (HMOs)
Platform Comparison
Precision Yeast vs. Legacy E. coli Systems
A direct comparison of our 3rd-generation yeast synthesis platform against traditional bacterial expression systems used by most competitors.
Data represents typical production parameters.
Product Portfolio
Key HMO Variants
Each variant is produced under our precision yeast platform and verified through Morika Bio Global Quality Unit.
C₁₈H₃₂O₁₄
2'-Fucosyllactose (2'-FL)
Most abundant HMO in human milk
C₂₆H₄₅NO₂₀
Lacto-N-neotetraose (LNnT)
Key bifidogenic factor
C₂₀H₃₇NO₁₅
Lacto-N-triose II (LNTr II)
First FDA GRAS globally via precision yeast synthesis
Technical Data
Typical Certificate of Analysis Parameters
Standardized COA parameters across the HMO portfolio. Full batch-specific COAs available upon request through The Vault.
HMO COA Parameters (Standardized)
| Parameter | Specification |
|---|---|
| Purity (HPLC) | 99.9% |
| pH (1% solution) | 6.7 Neutral |
| Moisture | < 0.2% |
| Ash | < 0.1% |
| Endotoxin (LPS) | Yeast-platform production route |
| Residual Solvents | Meets ICH Q3C |
| Heavy Metals (total) | < 5 ppm |
| Microbial Count | < 100 CFU/g |
| E. coli | Absent |
| Salmonella | Absent / 25g |
Application Areas
Designed for Critical Applications
Infant Formula
Gold-standard HMO supplementation for premium infant formula. Supports gut microbiome colonization and immune development. Endotoxin-free for maximum safety.
Adult Gut Health
Prebiotic supplementation for adult digestive wellness. Promotes beneficial Bifidobacterium growth and SCFA production.
Clinical Nutrition
Medical-grade HMOs for clinical nutrition products targeting immune modulation and gut barrier integrity.
Regulatory & Compliance
All certifications verified through Morika Bio Global Quality Unit. Developed and produced by Morika Bio.